Skip to main content
OpenTrials
Completed

NCT Number: NCT00104598

Framing Messages for Smoking Cessation With Bupropion - 6

This is a randomized study of message framing in individuals beginning a smoking cessation program utilizing bupropion SR and brief counseling, videos, and pamphlets.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Substance Abuse Treatment Unit

New Haven, Connecticut, 06519, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Exclusion criteria

  • Pregnant or nursing women, or women of child-bearing potential who are not using an adequate method of contraception
  • Psychiatric illnesses requiring psychotropic medications (i.e., psychosis, major depression, mania), or the presence of suicidality or homocidality
  • Current use of nicotine replacement therapies (i.e., nicotine patch, gum, or lozenges, nasal spray, or inhaler), bupropion (Zyban, Wellbutrin), or marijuana or current participation in another smoking cessation treatment
  • Presence of unstable medical conditions (i.e., cardiac, hepatic, renal disease, diabetes mellitus) that would make a trial of bupropion SR hazardous
  • Have taken monoamine oxidase inhibitors or metoprolol succinate within the past six weeks
  • History of anorexia nervosa or bulimia
  • Previous hypersensitivity to bupropion
  • History of alcohol or other drug dependence in the past one year
  • History of seizure disorder of any etiology (i.e., brain tumor, traumatic brain injury, substance-induced seizures, etc.)
  • Any finding that in the view of the principal investigator would compromise the subject's ability to fulfill the protocol visit schedule and visit requirements or put the subject at risk
  • Sharing home or work environment with current or past participant
  • No couples or participants who see each other every day

Treatment and study plan

bupropion

Drug

Smoking Abstinence Program

Behavioral

This investigation was a randomized controlled study of two framed message conditions for smoking cessation in combination with open label bupropion SR (300 mg/day). Two hundred fifty-eight cigarette smokers were randomly assigned to receive either gain- or loss-framed video and printed messages encouraging smoking abstinence. Preproduced video and printed information were chosen as the intervention media because of their reliability in delivering specific framed messages. All participants were seen at a community mental health center for 6 months and received a 7-week supply of bupropion SR.

Primary outcomes

  1. Smoking Cessation at 7 days

    Time frame: 7-day point prevalence abstinence

  2. Continuous Smoking Abstinence at 6 weeks

    Time frame: 6 weeks

    6-week continuous abstinence.

Sponsors and collaborators

Lead sponsor

Yale University

Other

Collaborators

  • National Institute on Drug Abuse (NIDA)

Registry information

Official study title

Framing Messages for Smoking Cessation With Buproprion

Important dates

Study start
2000
Primary completion
2004
Study completion
2006
First posted
Mar 2, 2005
Registry last updated
Aug 9, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.